Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II, Randomized Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (LEE011) in Patients With Advanced or Recurrent Endometrial Carcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03008408
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:26.774001+00:00
Published At
2026-02-11T00:00:00+00:00
Record Updated At
2026-02-11
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Recurrent Endometrial Carcinoma", "Recurrent Endometrial Endometrioid Adenocarcinoma", "Refractory Endometrial Carcinoma", "Refractory Endometrial Endometrioid Adenocarcinoma", "Stage III Uterine Corpus Cancer AJCC v8", "Stage IIIA Uterine Corpus Cancer AJCC v8", "Stage IIIB Uterine Corpus Cancer AJCC v8", "Stage IIIC Uterine Corpus Cancer AJCC v8", "Stage IIIC1 Uterine Corpus Cancer AJCC v8", "Stage IIIC2 Uterine Corpus Cancer AJCC v8", "Stage IV Uterine Corpus Cancer AJCC v8", "Stage IVA Uterine Corpus Cancer AJCC v8", "Stage IVB Uterine Corpus Cancer AJCC v8"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-02-11"
protocolSection.identificationModule.nctId
"NCT03008408"
protocolSection.identificationModule.officialTitle
"A Phase II, Randomized Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (LEE011) in Patients With Advanced or Recurrent Endometrial Carcinoma"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Recurrent Endometrial Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Endometrial Endometrioid Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Refractory Endometrial Carcinoma (protocolSection.conditionsModule.conditions)
  • Refractory Endometrial Endometrioid Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Stage III Uterine Corpus Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IIIA Uterine Corpus Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IIIB Uterine Corpus Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IIIC Uterine Corpus Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IIIC1 Uterine Corpus Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IIIC2 Uterine Corpus Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IV Uterine Corpus Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IVA Uterine Corpus Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IVB Uterine Corpus Cancer AJCC v8 (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.